Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The lawsuit seeks to force prisons to step up to the plate with hep C therapy and follows others filed in numerous states.
That’s the subject of a federal inquiry into the tech giant’s “Project Nightingale” partnership with Ascension.
This finding from a recent study applies to those who do not have cirrhosis when they are treated for the virus.
In a Phase IIa trial, the drug DUR-928 was associated with numerous positive outcomes after 28 days.
Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.
A U.S. appeals court upheld a judge’s previous decision to throw out a record-setting 2016 verdict in Merck’s favor.
Adults with chronic liver disease are more than twice as likely than those without the condition to have barriers to medical care.
Nevertheless, researchers are hoping to learn more from the study of the caspase inhibitor among people with non-alcoholic steatohepatitis.
A new classification system may more accurately reflect liver-related death trends in the United States.
The difference between hepatitis C virus and its antibodies can be confusing to understand, but important to know.
Drugs that have a favorable effect on biomarkers may still play a role in combination therapy, however.
Some study participants experienced hepatitis B surface antigen loss, considered a functional cure.
This is the first major study to assess an eight-week regimen in people with all genotypes of hep C and compensated cirrhosis.
Ninety-seven percent of the children were cured of hepatitis C.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.